Clinical Characteristics Associated with Return Visits to the Emergency Department after COVID-19 Diagnosis

Iltifat Husain, MD
James O’Neill, MD
Rachel Mudge, MD
Alicia Bishop, MD
K. Alexander Soltany, BA
Jesse Heinen, BS
Chase Countryman, MD
Dillon Casey, MD
David Cline, MD

Section Editor: Ioannis Koutroulis, MD, MBA, PhD
Submission history: Submitted April 15, 2021; Revision received September 20, 2021; Accepted September 11, 2021
Electronically published November 5, 2021
Full text available through open access at http://escholarship.org/uc/uciem_westjem
DOI: 10.5811/westjem.2021.9.52824

Introduction: Patients diagnosed with coronavirus disease 2019 (COVID-19) require significant healthcare resources. While published research has shown clinical characteristics associated with severe illness from COVID-19, there is limited data focused on the emergency department (ED) discharge population.

Methods: We performed a retrospective chart review of all ED-discharged patients from Wake Forest Baptist Health and Wake Forest Baptist Health Davie Medical Center between April 25-August 9, 2020, who tested positive for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) from a nasopharyngeal swab using real-time reverse transcription polymerase chain reaction (rRT-PCR) tests. We compared the clinical characteristics of patients who were discharged and had return visits within 30 days to those patients who did not return to the ED within 30 days.

Results: Our study included 235 adult patients who had an ED-performed SARS-CoV-2 rRT-PCR positive test and were subsequently discharged on their first ED visit. Of these patients, 57 (24.3%) had return visits to the ED within 30 days for symptoms related to COVID-19. Of these 57 patients, on return ED visits 27 were admitted to the hospital and 30 were not admitted. Of the 235 adult patients who were discharged, 11.5% (27) eventually required admission for COVID-19-related symptoms. With 24.3% patients having a return ED visit after a positive SARS-CoV-2 test and 11.5% requiring eventual admission, it is important to understand clinical characteristics associated with return ED visits. We performed multivariate logistic regression analysis of the clinical characteristics with independent association resulting in a return ED visit, which demonstrated the following: diabetes (odds ratio [OR] 2.990, 95% confidence interval [CI, 1.21-7.40, P = 0.0179); transaminitis (OR 8.973, 95% CI, 2.65-30.33, P = 0.004); increased pulse at triage (OR 1.04, 95% CI, 1.02-1.07, P = 0.0002); and myalgia (OR 4.43, 95% CI, 2.03-9.66, P = 0.0002).

Conclusion: As EDs across the country continue to treat COVID-19 patients, it is important to understand the clinical factors associated with ED return visits related to SARS-CoV-2 infection. We identified key clinical characteristics associated with return ED visits for patients initially diagnosed with SARS-CoV-2 infection: diabetes mellitus; increased pulse at triage; transaminitis; and complaint of myalgias. [West J Emerg Med. 2021;22(6)1257–1261.]
INTRODUCTION

In December 2019 a pathologic human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, causing coronavirus disease 2019 (COVID-19). In less than a year since its emergence, more than 730,368 deaths have been attributed to COVID-19 in the United States (US) with over 45,149,234 total cases reported.¹ Patients diagnosed with COVID-19 present not only a diagnostic challenge for the emergency department (ED), but also require significant healthcare resources.² One of the diagnostic challenges emergency physicians face is the prolonged clinical course of COVID-19. The median time from onset of illness to acute respiratory distress syndrome is 8-12 days, with the median time of onset of illness to intensive care unit admission 9.5-12 days. This variability in clinical course makes it difficult for emergency physicians to predict whether patients diagnosed with COVID-19 in the ED will have a return visit or admission. While published research has shown clinical characteristics associated with severe illness from COVID-19, there is limited data focusing on the ED discharge population.³,⁴

Significant hospital resources and operational changes are required to manage patients who present to the ED with symptoms concerning for COVID-19. These include use of personal protective equipment (PPE), negative pressure rooms, cohorting of patients, and more.⁵ In October–November 2020, a significant increase in COVID-19 was experienced in the ED setting. The US Centers for Disease Control and Prevention reported coronavirus-like illness (CLI) or a COVID-19 diagnostic code in the ED setting increasing from 2.7% of visits in early October to as high as 6.6% in late November 2020. In some states, such as New Mexico, CLI or COVID-19 diagnostic code visits have been as high as 16.5% of ED visits.⁶ This dramatic increase in COVID-19 diagnoses makes it critical to understand the clinical characteristics of these patients and how many may have return ED visits.

Currently there are no published reports of the clinical characteristics of patients who are discharged from the ED with a SARS-CoV-2-positive test and return within 30 days. Understanding these clinical characteristics would allow EDs to better prepare for return visits and allocate resources to help these patients in the outpatient setting once they are discharged. With EDs and hospitals experiencing constrained capacity, these proactive measures could enable hospital systems to reduce return visits of patients with COVID-19 and improve operational planning for them.

METHODS

We conducted a retrospective chart review of all ED-discharged patients from the Wake Forest Baptist Health and Wake Forest Baptist Health Davie Medical Center who had an ED-positive laboratory SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) test resulting from a nasopharyngeal swab between April 25–August 9, 2020. We compared the clinical characteristics of patients who were discharged and had return visits within 30 days to those patients who did not return to the ED within 30 days. This study was approved by the Biomedical Institutional Review Board of Wake Forest School of Medicine.

Of patients discharged from the ED with positive rRT-PCR testing, we included patients aged 18 and older. Patients’ health records underwent individual chart review to determine whether they had a return visit to the ED within 30 days for COVID-19-related symptoms. Patients who did not have a return visit to the ED within 30 days for COVID-19 related symptoms comprised our control cohort of no return ED visits. We analyzed the data using SAS 9.4 (SAS Institute, Inc., Cary, NC). Chi-square test was used to compare frequencies of categorical variables between discharged ED patients with a positive ED rRT-PCR for SARS-CoV-2 who returned after their index ED visit and those patients who did not return. We used Student’s t-tests or Wilcoxon signed-rank tests to compare continuous variables between groups. Logistic regression was used for multivariate analysis of those variables that were independently associated with return to the ED.

RESULTS

Our study included 235 adult patients who had an ED-performed SARS-CoV-2 rRT-PCR positive test and were subsequently discharged on their first ED visit. Of these patients, 57 (24.3%) had return visits to the ED within 30 days for symptoms related to COVID-19. Of these 57 patients, on return ED visits 27 were admitted to the hospital and 30 were not admitted. Of the 235 adult patients who were discharged, 11.5% (27) eventually required admission for COVID-19 related symptoms. With 24.3% of patients having a return ED visit after a positive SARS-CoV-2 test and 11.5% requiring eventual admission, it is important to understand clinical characteristics associated with return ED visits.

Table 1 lists clinical characteristics and their univariate association with return to the ED. The chronic conditions that we found significantly associated with return ED visits were diabetes (OR 3.06, 95% CI, 1.52-6.13, P = 0.002) and hypertension (OR 2.18, 95% CI, 1.17-4.05, P = 0.013). Patients between ages 50-69 were more likely to have a return ED visit (OR 1.89, 95% CI, 1.02-3.50, P = 0.042). While patients with return ED visits had a higher percentage of abnormal chest radiographs at their index ED visit than those who did not return (42.1% to 28.1%), this was not statistically significant. Lab abnormalities significantly associated with higher return visits were transaminitis (OR 3.99, 95% CI, 1.53-10.4, P < 0.001); thrombocytopenia (OR 3.0, 95% CI, 1.2-7.2, P = 0.012); and abnormal glomerular filtration rate (OR 4.1, 95% CI, 1.2-13.9, P = 0.025). Interestingly, diagnostic markers used for risk stratification, such as D-dimer and lymphopenia, were not significantly associated with higher return visits to the ED. Neither were health insurance status or race significantly associated.
with higher return visits to the ED. We analyzed triage and discharge vital signs from patient index visits and found heart rate ≥ 90 during triage and discharge was significantly associated with return ED visits.

Table 2 lists those clinical characteristics that retained independent association with a return visit to the ED after the index visit to the ED due to COVID-19. These clinical characteristics included increased pulse at triage, (OR 1.043,

| Clinical characteristics (Initial ED visit) | Total N = 235 | No return ED visit N = 178 (% cohort) | Return ED visit N = 57 (% cohort) | Odds ratio (95% CI) | Standard error | P-value |
|---------------------------------------------|---------------|--------------------------------------|----------------------------------|---------------------|----------------|---------|
| **Age**                                     |               |                                      |                                  |                     |                |         |
| 18-49                                       | 151           | 120 (67.4)                           | 31 (54.4)                        | 0.58 (0.31-1.06)    | 0.31           | 0.076   |
| 50-69                                       | 77            | 52 (29.2)                            | 25 (43.9)                        | 1.89 (1.02-3.50)    | 0.31           | 0.042   |
| >70                                         | 7             | 6 (3.3)                              | 1 (1.8)                          | 1.16 (0.39-3.28)    | 0.54           | 0.827   |
| **Chronic conditions**                      |               |                                      |                                  |                     |                |         |
| Asthma or COPD                              | 30            | 24 (13.5)                            | 6 (10.5)                         | 0.76 (0.29-1.95)    | 0.48           | 0.561   |
| Diabetes                                    | 44            | 25 (14.0)                            | 19 (33.3)                        | 3.06 (1.52-6.13)    | 0.35           | 0.002   |
| Hypertension                                | 72            | 47 (26.4)                            | 25 (43.9)                        | 2.18 (1.17-4.05)    | 0.32           | 0.013   |
| **Vital signs**                             |               |                                      |                                  |                     |                |         |
| HR < 89 (triage)                            | 96            | 80 (44.9)                            | 16 (28.1)                        | 0.478 (0.24-0.91)   | 0.33           | 0.026   |
| HR > 90 (triage)                            | 139           | 98 (55.1)                            | 41 (71.9)                        | 2.09 (1.09-4.00)    | 0.33           | 0.026   |
| HR < 89 (discharge)                         | 168           | 138 (77.5)                           | 30 (52.6)                        | 0.322 (0.17-0.60)   | 0.32           | 0.001   |
| HR > 90 (discharge)                         | 67            | 40 (22.5)                            | 27 (47.4)                        | 3.11 (1.66-5.82)    | 0.32           | 0.001   |
| **Lab / imaging**                           |               |                                      |                                  |                     |                |         |
| Chest CXR normal                            | 88            | 69 (38.8)                            | 19 (33.3)                        | 0.79 (0.41-1.47)    | 0.32           | 0.461   |
| Chest CXR abnormal                          | 74            | 50 (28.1)                            | 24 (42.1)                        | 1.86 (1.00-3.45)    | 0.32           | 0.047   |
| Chest CXR not ordered                       | 73            | 59 (33.1)                            | 14 (24.6)                        | 0.65 (0.33-1.29)    | 0.34           | 0.225   |
| Transaminitis                               | 19            | 9 (5.1)                              | 10 (52.6)                        | 3.99 (1.53-10.4)    | 0.48           | <0.0001 |
| Thrombocytopenia                            | 24            | 13 (7.3)                             | 11 (19.3)                        | 3.0 (1.2-7.2)       | 0.44           | 0.012   |
| Lymphopenia                                 | 34            | 24 (13.5)                            | 10 (17.5)                        | 1.36 (0.6-3.6)      | 0.41           | 0.449   |
| D-dimer positive                            | 9             | 7 (3.9)                              | 2 (3.5)                          | 0.88 (0.17-4.4)     | 0.81           | 0.885   |
| GFR abnormal                                | 11            | 5 (2.8)                              | 6 (10.5)                         | 4.1 (1.2-13.9)      | 0.62           | 0.025   |
| Labs not ordered                            | 109           | 89 (50.0)                            | 20 (35.1)                        | 0.541 (0.29-1.00)   | 0.31           | 0.051   |
| Health insurance (Y)                        | 112           | 81 (45.5)                            | 31 (54.4)                        | 1.47 (0.80-2.67)    | 0.31           | 0.212   |
| **Weight**                                  |               |                                      |                                  |                     |                |         |
| BMI < 25                                    | 59            | 49 (27.5)                            | 10 (17.5)                        | 0.56 (0.26-1.19)    | 0.39           | 0.134   |
| Overweight (BMI 25 to 29.9)                 | 52            | 38 (21.3)                            | 14 (24.6)                        | 1.2 (0.60-2.42)     | 0.36           | 0.611   |
| Obesity (BMI > 30)                          | 124           | 91 (51.1)                            | 33 (57.9)                        | 1.31 (0.72-2.40)    | 0.31           | 0.375   |
| **Race / Ethnicity**                        |               |                                      |                                  |                     |                |         |
| Asian, non-Hispanic                         | 5             | 4 (2.2)                              | 1 (1.8)                          | 0.777 (0.08-7.10)   | 0.17           | 0.746   |
| Black, non-Hispanic                         | 50            | 37 (20.8)                            | 13 (22.8)                        | 1.13 (0.55-2.31)    | 0.37           | 0.746   |
| Other race, non-Hispanic                    | 5             | 3 (1.7)                              | 2 (3.5)                          | 2.21 (0.35-13.02)   | 0.93           | 0.417   |
| White, non-Hispanic                         | 61            | 46 (25.8)                            | 15 (26.3)                        | 1.03 (0.52-2.02)    | 0.35           | 0.943   |
| Hispanic                                    | 114           | 88 (49.4)                            | 26 (45.6)                        | 0.858 (0.47-1.56)   | 0.31           | 0.615   |

ED, emergency department; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, heart rate; CXR, chest radiograph; GFR, glomerular filtration rate; BMI, body mass index.
95% CI, 1.020-1.065, \( P = 0.0002 \); myalgia, (OR 4.427, 95% CI, 2.028-9.663, \( P = 0.0002 \); history of diabetes mellitus, (OR 2.990, 95% CI, 1.208-7.403, \( P = 0.0179 \); and transaminitis (OR 8.973, 95% CI, 2.654-30.333, \( P = 0.0004 \). Transaminitis was defined as any abnormal elevation in aspartate aminotransferase or alanine aminotransferase above the laboratory-defined upper limit of normal.

**DISCUSSION**

Our study shows the key clinical characteristics associated with ED return visits for patients discharged with ED-positive SARS-CoV-2 testing. After controlling for other clinical characteristics, multivariate logistic regression found that history of diabetes mellitus, a complaint of myalgia, an increased pulse at triage, and transaminitis were independently associated with a return ED visit. As EDs across the country continue to treat COVID-19 patients, it is important to understand clinical factors associated with return visits to prevent unnecessary COVID-19 return visits. The clinical characteristics we found associated with ED return visits will need to be validated independently. This analysis is part of a forthcoming study encompassing multiple EDs and a larger patient population.

We encourage hospital operational teams to focus on the ED-discharge patient populations we have identified in our study to proactively prepare and attempt to prevent unnecessary ED evaluations in a time when hospital capacity is limited.

**LIMITATIONS**

Limitations of our study include possible sample bias. Our study population was made up of 49.3% Hispanics, 21.6% Black/non-Hispanic, and 26.4% White/non-Hispanic. However, this high percentage of Hispanics and Black/non-Hispanic does correlate with known disproportionate rates of SARS-CoV-2 infection in the US by race. A second limitation is the study’s duration (106 days) and the number of total patients (235).

**CONCLUSION**

Our study identified key clinical characteristics associated with return ED visits for patients initially diagnosed with SARS-CoV-2 infection: diabetes mellitus; increased pulse at triage; transaminitis; and complaint of myalgias.

---

**Table 2. Multivariate logistic regression: clinical characteristics independently associated with return to the emergency department after the initial visit for COVID-19 infection.**

| Clinical characteristic          | Odds ratio | 95% Confidence interval | \( P \)-value |
|---------------------------------|------------|-------------------------|--------------|
| Pulse at triage (increasing)*   | 1.04       | 1.02                    | 1.07         | 0.0002       |
| Myalgia                         | 4.43       | 2.03                    | 9.66         | 0.0002       |
| History of diabetes mellitus    | 2.99       | 1.21                    | 7.40         | 0.0179       |
| Transaminitis                   | 8.97       | 2.65                    | 30.33        | 0.0004       |

*Continuous variable; as pulse increased, the odds ratio increased 1.043 per each beat per minute.

---

**REFERENCES**

1. Centers for Disease Control and Prevention. CDC COVID Data Tracker. 2020. Available at: https://covid.cdc.gov/covid-data-tracker/. Accessed October 21, 2021.

2. Ferguson J, Rosser JI, Quintero O, et al. Characteristics and outcomes of coronavirus disease patients under nonsurge conditions, Northern California, USA, March-April 2020. Emerg Infect Dis. 2020;26(8):1679-85.

3. Lavery AM, Preston LE, Ko JY, et al. Characteristics and outcomes of coronavirus disease patients under nonsurge conditions, Northern California, USA, March-April 2020. Emerg Infect Dis. 2020;26(8):1679-85.

4. Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed 2019 novel coronavirus (2019-nCoV) Infection. 2020. Available at: https://asprtracie.hhs.gov/technical-resources/resource/9684/interim-infection-prevention-and-control-recommendations-for-healthcare-personnel-during-the-coronavirus-disease-2019-covid-19-pandemic. Accessed December 10, 2020.

5. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic. 2021. Available at: https://asprtracie.hhs.gov/technical-resources/resource/9684/interim-infection-prevention-and-control-recommendations-for-healthcare-personnel-during-the-coronavirus-disease-2019-covid-19-pandemic. Accessed December 10, 2020.

6. Centers for Disease Control and Prevention. CDC COVID Data
Tracker United States Trends in Emergency Department Visits. 2020. Available at: https://covid.cdc.gov/covid-data-tracker/#ed-visits. Accessed December 1, 2020.

7. Centers for Disease Control and Prevention. COVID-19 hospitalization and death by race/ethnicity. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html. Accessed December 15, 2020.